Press release content from Accesswire. The AP news staff was not involved in its creation. Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker February 18, 2021 GMT Parsortix system able to harvest difficult-to-detect mesenchymal CTCs Metastatic biomarker Cyr61 found by researchers in 40% of breast cancer CTCs may be a novel therapeutic target in treating drug-resistant breast cancers GUILDFORD, SURREY / ACCESSWIRE / February 18, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University Medical Centre Hamburg-Eppendorf, Germany, has published new research in the peer reviewed journal Cancers, that demonstrates the ability of the Parsortix® system to harvest circulating tumour cells (CTCs) with a mesenchymal phenotype, which can be used to detect the metastatic biomarker cysteine-rich angiogenetic inducer 61 (Cyr61) in breast cancer patients.